BONE AND RENAL SAFETY OF TENOFOVIR ALAFENAMIDE ( TAF) AT 8 YEARS IN CHRONIC HBV ( CHB) PATIENTS WITH UNDERLYING RISK FACTORS FOR USE OF TENOFOVIR DISOPROXIL FUMARATE ( TDF)

被引：0

作者：

Buti, Maria ^{[1
,2
]}

Gane, Edward J. ^{[3
]}

Agarwal, Kosh ^{[4
]}

Wong, Grace Lai-Hung C. ^{[5
]}

Lim, Young-Suk ^{[6
]}

Chen, Chi-Yi ^{[7
]}

Lim, Seng Gee ^{[8
]}

Yatsuhashi, Hiroshi ^{[9
]}

Fung, Scott K. ^{[10
]}

Abramov, Frida ^{[11
]}

Wang, Hongyuan ^{[11
]}

Yee, Leland J. ^{[11
]}

Flaherty, John F. ^{[11
]}

Pan, Calvin Q. ^{[12
]}

Marcellin, Patrick ^{[13
]}

机构：

[1] Hosp Univ Vall Dhebron, Barcelona, Spain

[2] Ciberehd Inst Carlos III, Madrid, Spain

[3] Univ Auckland, Auckland, New Zealand

[4] Kings Coll Hosp London, Inst Liver Studies, London, England

[5] Chinese Univ Hong Kong, MDAC, Hong Kong, Peoples R China

[6] Univ Ulsan, Coll Med, Asan Med Ctr, Seoul, South Korea

[7] Chiayi Christian Hosp, Chiayi, Taiwan

[8] Natl Univ Hlth Syst, Singapore, Singapore

[9] Natl Hosp Org Nagasaki Med Ctr, Clin Res Ctr, Nagasaki, Japan

[10] Univ Toronto, Dept Med, Toronto, ON, Canada

[11] Gilead Sci Inc, Foster City, CA 94404 USA

[12] NYU, NYU Langone Hlth, Grossman Sch Med, New York, NY USA

[13] Univ Paris, Hop Beaujon, AP HP, Paris, France

来源：

HEPATOLOGY | 2023年 / 78卷

关键词：

D O I：

暂无

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

1405C

引用

页码：S507 / S509

页数：3

共 50 条

[1] EFFICACY AND SAFETY OF TENOFOVIR ALAFENAMIDE (TAF) AT 96 WEEKS IN CHRONIC HBV (CHB) PATIENTS WITH RISK FACTORS FOR USE OF TENOFOVIR DISOPROXIL FUMARATE (TDF) [J].

Chan, Henry Lik-Yuen ;

Buti, Maria ;

Flisiak, Robert ;

Ryder, Stephen ;

Streinu-Cercel, Adrian ;

Flaherty, John F. ;

Gaggar, Anuj ;

Mo, Shuyuan ;

Subramanian, G. Mani ;

Zoulim, Fabrian ;

Andreone, Pietro ;

Marcellin, Patrick .

GUT, 2018, 67 :A97-A97

[2] Efficacy and Safety of Tenofovir Alafenamide (TAF) at 96 Weeks in Chronic HBV (CHB) Patients with Risk Factors for Use of Tenofovir Disoproxil Fumarate (TDF) [J].

Buti, Maria ;

Stepanova, Tatjana ;

Celen, Mustafa K. ;

Flisiak, Robert ;

Ryder, Stephen D. ;

Streinu-Cercel, Adrian ;

Gurel, Selim ;

Flaherty, John F. ;

Gaggar, Anuj ;

Suri, Vithika ;

Mo, Shuyuan ;

Subramanian, Mani ;

Nurmukhametova, Elena ;

Zoulim, Fabien ;

Andreone, Pietro ;

Marcellin, Patrick .

HEPATOLOGY, 2017, 66 :488A-488A

[3] FACTORS ASSOCIATED WITH A LACK OF VIRAL SUPPRESSION IN CHRONIC HBV ( CHB) PATIENTS AFTER 8 YEARS OF TREATMENT WITH TENOFOVIR ALAFENAMIDE ( TAF) OR TENOFOVIR DISOPROXIL FUMARATE ( TDF) FOLLOWED BY TAF TREATMENT [J].

Gane, Edward J. ;

Buti, Maria ;

Fung, Scott K. ;

Chan, Henry Lik Yuen ;

Izumi, Namiki ;

Chuang, Wan Long ;

Ahn, Sang Hoon ;

Mehta, Rajiv M. ;

Gurel, Selim ;

Abramov, Frida ;

Yee, Leland J. ;

Wang, Hongyuan ;

Mateo, Roberto ;

Flaherty, John F. ;

Ma, Xiaoli ;

Pan, Calvin Q. ;

Lim, Young-Suk ;

Marcellin, Patrick .

HEPATOLOGY, 2023, 78 :S519-S520

[4] SAFETY AND EFFICACY AT 48 WEEKS AFTER SWITCHING FROM TENOFOVIR DISOPROXIL FUMARATE (TDF) TO TENOFOVIR ALAFENAMIDE (TAF) IN CHRONIC HBV PATIENTS WITH RISK FACTORS FOR TDF USE [J].

Buti, Maria ;

Lampertico, Pietro ;

Lim, Young-Suk ;

Agarwal, Kosh ;

Fung, Scott K. ;

Tsang, Owen ;

Elkhashab, Magdy ;

Kao, Jia-Horng ;

Luis Calleja, Jose ;

Khalili, Mandana ;

Ravendhran, Natarajan ;

Tan, Susanna ;

Flaherty, John F. ;

Gaggar, Anuj ;

Lau, Audrey H. ;

Wu, George ;

Hann, Hie-Won L. ;

Pan, Calvin ;

Kim, Hyung Joon ;

Kennedy, Patrick T. F. ;

Chan, Henry Lik Yuen .

HEPATOLOGY, 2019, 70 :301A-301A

[5] BONE AND RENAL SAFETY ARE IMPROVED IN CHRONIC HBV PATIENTS 1 YEAR AFTER SWITCHING TO TENOFOVIR ALAFENAMIDE (TAF) FROM TENOFOVIR DISOPROXIL FUMARATE (TDF) [J].

Chan, Henry Lik Yuen ;

Seto, Wai Kay ;

Buti, Maria ;

Izumi, Namiki ;

Lim, Young-Suk ;

Kao, Jia-Horng ;

Streinu-Cercel, Adrian ;

Nurmukhametova, Elena ;

Ma, Xiaoli ;

Tabak, Fehmi ;

Jablkowski, Maciej ;

Suri, Vithika ;

Flaherty, John ;

Lau, Audrey ;

Gaggar, Anuj ;

Mo, Shuyuan ;

Chowdhury, Abhijit ;

Fung, Scott ;

Chuang, Wan-Long ;

Gane, Edward .

GUT, 2019, 68 :A141-A142

[6] Bone and Renal Safety Are Improved in Chronic HBV Patients 1 Year after Switching to Tenofovir Alafenamide (TAF) from Tenofovir Disoproxil Fumarate (TDF) [J].

Seto, Wai Kay Walter ;

Buti, Maria ;

Izumi, Namiki ;

Lim, Young-Suk ;

Kao, Jia-Horng ;

Streinu-Cercel, Adrian ;

Nurmukhametova, Elena ;

Ma, Xiaoli ;

Tabak, Fehmi ;

Jablkowski, Maciej ;

Suri, Vithika ;

Flaherty, John F. ;

Lau, Audrey H. ;

Gaggar, Anuj ;

Mo, Shuyuan ;

Chowdhury, Abhijit ;

Fung, Scott K. ;

Chuang, Wan-Long ;

Gane, Edward J. .

HEPATOLOGY, 2018, 68 :240A-241A

[7] Safety of tenofovir alafenamide (TAF) in patients with a history of proximal renal tubulopathy on tenofovir disoproxil fumarate (TDF) [J].

Hamzah, L. ;

Jones, R. ;

Bailey, A. ;

Williams, D. ;

Johnson, M. ;

Ibrahim, F. ;

Musso, C. ;

Burling, K. ;

Campbell, L. ;

Post, F. .

HIV MEDICINE, 2019, 20 :8-9

[8] 1 YEAR SAFETY AND EFFICACY DATA IN CHRONIC HBV PATIENTS WITH RISK FACTORS FOR TENOFOVIR DISOPROXIL FUMARATE (TDF) AFTER SWITCHING FROM TDF TO TENOFOVIR ALAFENAMIDE (TAF) [J].

Pan, Calvin Q. ;

Gane, Edward ;

Seto, Wai-Kay ;

Janssen, Harry L. ;

Caruntu, Florin ;

Kim, Hyung Joon ;

Abdurakhmanov, Dzhamal ;

Nishiguchi, Shuhei ;

Bae, Ho ;

Mo, Shuyuan ;

Suri, Vithika ;

Gaggar, Anuj ;

Flaherty, John F. ;

Kao, Jia-Horng ;

Brunetto, Maurizia Rossana ;

Buti, Maria .

GASTROENTEROLOGY, 2018, 154 (06) :S1132-S1133

[9] Bone and renal safety are improved in chronic HBV patients switched to tenofovir alafenamide (TAF) after either 2 or 3 years of prior tenofovir disoproxil fumarate (TDF) treatment [J].

Buti, Maria ;

Izumi, Namiki ;

Lim, Young-Suk ;

Janssen, Harry ;

Kao, Jia-Horng ;

Streinu-Cercel, Adrian ;

Nurmukhametova, Elena ;

Ma, Xiaoli ;

Fehmi, Tabak ;

Jablkowski, Maciej ;

Suri, Vithika ;

Flaherty, John F. ;

Lau, Audrey ;

Gaggar, Anuj ;

Mo, Shuyuan ;

Chaudhuri, Abhijit ;

Fung, Scott ;

Chuang, Wan-Long ;

Gane, Edward .

JOURNAL OF HEPATOLOGY, 2019, 70 (01) :E457-E458

[10] 48-WEEK SAFETY AND EFFICACY OF SWITCHING TO TENOFOVIR ALAFENAMIDE (TAF) FROM TENOFOVIR DISOPROXIL FUMARATE (TDF) IN CHRONIC HBV ASIAN PATIENTS WITH TDF RISK FACTORS (RF) [J].

Ahn, Sang Hoon ;

Kao, Jia-Horng ;

Hann, Hie-Won ;

Scott, Fung ;

Trinh, Huy ;

Nguyen, Tuan Trong ;

Paik, Seung Woon ;

Gaggar, Anuj ;

Flaherty, John ;

Yee, Leland ;

Jump, Belinda ;

Sethi, Shalini ;

Wu, George ;

Chan, Carol Yee Kwan .

GUT, 2020, 69 :A73-A74

← 1 2 3 4 5 →